
1. Int J Pharm. 2020 Oct 15;588:119733. doi: 10.1016/j.ijpharm.2020.119733. Epub
2020 Aug 5.

Characterization and in vitro evaluation of a vaginal gel containing
Lactobacillus crispatus for the prevention of gonorrhea.

N'Guessan Gnaman KC(1), Bouttier S(2), Yeo A(3), Aka Any-Grah AAS(4), Geiger
S(5), Huang N(5), Nicolas V(6), Villebrun S(5), Faye-Kette H(3), Ponchel G(5),
Koffi AA(4), Agnely F(7).

Author information: 
(1)Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92290
Châtenay-Malabry, France; Laboratoire de Pharmacie Galénique, Cosmétologie et
Législation Pharmaceutique, UFR des Sciences Pharmaceutiques et Biologiques
d'Abidjan, Université Félix Houphouet-Boigny, 01 BP V 34 Abidjan 01, Côte
d'Ivoire.
(2)INRAE, AgroParisTech, MIcalis Institute, Équipe Bactéries pathogènes et santé,
Université Paris-Saclay, 92290 Châtenay-Malabry, France.
(3)Institut Pasteur, Departement de microbiologie, Unité des agents du tractus
génital, Abidjan, Côte d'Ivoire.
(4)Laboratoire de Pharmacie Galénique, Cosmétologie et Législation
Pharmaceutique, UFR des Sciences Pharmaceutiques et Biologiques d'Abidjan,
Université Félix Houphouet-Boigny, 01 BP V 34 Abidjan 01, Côte d'Ivoire.
(5)Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92290
Châtenay-Malabry, France.
(6)Université Paris-Saclay, SFR-UMS-IPSIT, Plateforme d'imagerie cellulaire
MIPSIT, 92290 Châtenay-Malabry, France.
(7)Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92290
Châtenay-Malabry, France. Electronic address:
florence.agnely@universite-paris-saclay.fr.

The increasing resistance of Neisseria gonorrhoeae to any current antibiotic
treatment and the difficulties associated with the use of prevention means such
as condom urge the need for alternative methods to prevent this sexually
transmitted infection. In this work, a prevention strategy based on the use of a 
vaginal gel containing Lactobacilli was assessed in vitro. A Lactobacillus
crispatus strain (ATCC 33197) was selected based on the published data on its
ability to inhibit Neisseria gonorrhoeae. Its probiotic properties were first
characterized. Then, a thermo-sensitive hydrogel containing 21.5% of poloxamer
407, 1% of sodium alginate and 9log10 CFU of Lactobacillus crispatus per gel
sample (5 g) was developed. The gelation temperature and the rheological
characteristics of this formulation appeared suitable for a vaginal
administration. Lactobacillus crispatus was viable in the gel for six months
although a large amount of the bacteria was not culturable. The ability of
Lactobacillus crispatus to inhibit Neisseria gonorrhoeae was still observed with 
the gel. Such system, thus, appeared promising for the prevention of gonorrhea.

Copyright © 2020 Elsevier B.V. All rights reserved.

DOI: 10.1016/j.ijpharm.2020.119733 
PMID: 32768529 

